These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1079 related items for PubMed ID: 34145929

  • 1. MUSASHI-2 confers resistance to third-generation EGFR-tyrosine kinase inhibitor osimertinib in lung adenocarcinoma.
    Yiming R, Takeuchi Y, Nishimura T, Li M, Wang Y, Meguro-Horike M, Kohno T, Horike SI, Nakata A, Gotoh N.
    Cancer Sci; 2021 Sep; 112(9):3810-3821. PubMed ID: 34145929
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of Bcl-2 and Bcl-xL overcomes the resistance to the third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer.
    Lu Y, Bian D, Zhang X, Zhang H, Zhu Z.
    Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33200796
    [Abstract] [Full Text] [Related]

  • 3. AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells.
    Kim D, Bach DH, Fan YH, Luu TT, Hong JY, Park HJ, Lee SK.
    Cell Death Dis; 2019 May 01; 10(5):361. PubMed ID: 31043587
    [Abstract] [Full Text] [Related]

  • 4. Long Non-Coding RNA CRNDE Is Involved in Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant Lung Cancer via eIF4A3/MUC1/EGFR Signaling.
    Takahashi S, Noro R, Seike M, Zeng C, Matsumoto M, Yoshikawa A, Nakamichi S, Sugano T, Hirao M, Matsuda K, Hamada M, Gemma A.
    Int J Mol Sci; 2021 Apr 13; 22(8):. PubMed ID: 33924522
    [Abstract] [Full Text] [Related]

  • 5. A novel osimertinib-resistant human lung adenocarcinoma cell line harbouring mutant EGFR and activated IGF1R.
    Makimoto G, Ninomiya K, Kubo T, Sunami R, Kato Y, Ichihara E, Ohashi K, Rai K, Hotta K, Tabata M, Maeda Y, Kiura K.
    Jpn J Clin Oncol; 2021 May 28; 51(6):956-965. PubMed ID: 33829270
    [Abstract] [Full Text] [Related]

  • 6. Overcoming acquired resistance of gefitinib in lung cancer cells without T790M by AZD9291 or Twist1 knockdown in vitro and in vivo.
    Liu Z, Gao W.
    Arch Toxicol; 2019 Jun 28; 93(6):1555-1571. PubMed ID: 30993382
    [Abstract] [Full Text] [Related]

  • 7. Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.
    Fukuda K, Otani S, Takeuchi S, Arai S, Nanjo S, Tanimoto A, Nishiyama A, Naoki K, Yano S.
    Cancer Sci; 2021 Sep 28; 112(9):3784-3795. PubMed ID: 34145930
    [Abstract] [Full Text] [Related]

  • 8. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.
    Li Y, Zang H, Qian G, Owonikoko TK, Ramalingam SR, Sun SY.
    Cancer; 2020 Mar 15; 126(6):1339-1350. PubMed ID: 31821539
    [Abstract] [Full Text] [Related]

  • 9. Let-7c regulated epithelial-mesenchymal transition leads to osimertinib resistance in NSCLC cells with EGFR T790M mutations.
    Li XF, Shen WZ, Jin X, Ren P, Zhang J.
    Sci Rep; 2020 Jul 08; 10(1):11236. PubMed ID: 32641854
    [Abstract] [Full Text] [Related]

  • 10. ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non-Small Cell Lung Cancer.
    Okura N, Nishioka N, Yamada T, Taniguchi H, Tanimura K, Katayama Y, Yoshimura A, Watanabe S, Kikuchi T, Shiotsu S, Kitazaki T, Nishiyama A, Iwasaku M, Kaneko Y, Uchino J, Uehara H, Horinaka M, Sakai T, Tanaka K, Kozaki R, Yano S, Takayama K.
    Clin Cancer Res; 2020 May 01; 26(9):2244-2256. PubMed ID: 31953310
    [Abstract] [Full Text] [Related]

  • 11. Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI.
    Weng CH, Chen LY, Lin YC, Shih JY, Lin YC, Tseng RY, Chiu AC, Yeh YH, Liu C, Lin YT, Fang JM, Chen CC.
    Oncogene; 2019 Jan 01; 38(4):455-468. PubMed ID: 30111817
    [Abstract] [Full Text] [Related]

  • 12. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
    Hayakawa D, Takahashi F, Mitsuishi Y, Tajima K, Hidayat M, Winardi W, Ihara H, Kanamori K, Matsumoto N, Asao T, Ko R, Shukuya T, Takamochi K, Hayashi T, Suehara Y, Takeda Nakamura I, Ueno T, Kohsaka S, Mano H, Takahashi K.
    Thorac Cancer; 2020 Jan 01; 11(1):140-149. PubMed ID: 31758670
    [Abstract] [Full Text] [Related]

  • 13. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma.
    Kishikawa T, Kasai T, Okada M, Nakachi I, Soda S, Arai R, Takigami A, Sata M.
    Thorac Cancer; 2020 Apr 01; 11(4):935-942. PubMed ID: 32129931
    [Abstract] [Full Text] [Related]

  • 14. Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma.
    Bousquet Mur E, Bernardo S, Papon L, Mancini M, Fabbrizio E, Goussard M, Ferrer I, Giry A, Quantin X, Pujol JL, Calvayrac O, Moll HP, Glasson Y, Pirot N, Turtoi A, Cañamero M, Wong KK, Yarden Y, Casanova E, Soria JC, Colinge J, Siebel CW, Mazieres J, Favre G, Paz-Ares L, Maraver A.
    J Clin Invest; 2020 Feb 03; 130(2):612-624. PubMed ID: 31671073
    [Abstract] [Full Text] [Related]

  • 15. P21-activated kinase 2-mediated β-catenin signaling promotes cancer stemness and osimertinib resistance in EGFR-mutant non-small-cell lung cancer.
    Yi Y, Li P, Huang Y, Chen D, Fan S, Wang J, Yang M, Zeng S, Deng J, Lv X, Luo K, He Z, Liu H.
    Oncogene; 2022 Sep 03; 41(37):4318-4329. PubMed ID: 35986102
    [Abstract] [Full Text] [Related]

  • 16. Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion.
    Piotrowska Z, Isozaki H, Lennerz JK, Gainor JF, Lennes IT, Zhu VW, Marcoux N, Banwait MK, Digumarthy SR, Su W, Yoda S, Riley AK, Nangia V, Lin JJ, Nagy RJ, Lanman RB, Dias-Santagata D, Mino-Kenudson M, Iafrate AJ, Heist RS, Shaw AT, Evans EK, Clifford C, Ou SI, Wolf B, Hata AN, Sequist LV.
    Cancer Discov; 2018 Dec 03; 8(12):1529-1539. PubMed ID: 30257958
    [Abstract] [Full Text] [Related]

  • 17. Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients.
    Yang Z, Yang N, Ou Q, Xiang Y, Jiang T, Wu X, Bao H, Tong X, Wang X, Shao YW, Liu Y, Wang Y, Zhou C.
    Clin Cancer Res; 2018 Jul 01; 24(13):3097-3107. PubMed ID: 29506987
    [Abstract] [Full Text] [Related]

  • 18. Targeting DNA-PK overcomes acquired resistance to third-generation EGFR-TKI osimertinib in non-small-cell lung cancer.
    Liang XM, Qin Q, Liu BN, Li XQ, Zeng LL, Wang J, Kong LP, Zhong DS, Sun LL.
    Acta Pharmacol Sin; 2021 Apr 01; 42(4):648-654. PubMed ID: 33414509
    [Abstract] [Full Text] [Related]

  • 19. 1,25-dihydroxyvitamin D3 signaling-induced decreases in IRX4 inhibits NANOG-mediated cancer stem-like properties and gefitinib resistance in NSCLC cells.
    Jia Z, Zhang Y, Yan A, Wang M, Han Q, Wang K, Wang J, Qiao C, Pan Z, Chen C, Hu D, Ding X.
    Cell Death Dis; 2020 Aug 20; 11(8):670. PubMed ID: 32820157
    [Abstract] [Full Text] [Related]

  • 20. Targeting pyruvate dehydrogenase kinase 1 overcomes EGFR C797S mutation-driven osimertinib resistance in non-small cell lung cancer.
    Park W, Wei S, Xie CL, Han JH, Kim BS, Kim B, Jin JS, Yang ES, Cho MK, Ryu D, Yang HX, Bae SJ, Ha KT.
    Exp Mol Med; 2024 May 20; 56(5):1137-1149. PubMed ID: 38689087
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 54.